Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives $199.53 Consensus Target Price from Brokerages

Palvella Therapeutics, Inc. (NASDAQ:PVLA) has received a consensus recommendation of “Moderate Buy” from the sixteen brokerages that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, fourteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $199.5333.

A number of equities research analysts recently commented on PVLA shares. Chardan Capital reissued a “buy” rating and set a $240.00 target price on shares of Palvella Therapeutics in a research report on Thursday, May 21st. HC Wainwright lifted their price target on shares of Palvella Therapeutics from $255.00 to $270.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. Stephens reaffirmed an “overweight” rating and set a $220.00 price target on shares of Palvella Therapeutics in a research report on Thursday, May 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Palvella Therapeutics in a research report on Monday, June 29th. Finally, Wall Street Zen lowered Palvella Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 11th.

Insider Transactions at Palvella Therapeutics

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $110.73, for a total value of $476,360.46. Following the completion of the sale, the chief operating officer directly owned 2,154 shares in the company, valued at approximately $238,512.42. This trade represents a 66.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 17.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Palvella Therapeutics

A number of large investors have recently modified their holdings of PVLA. KBC Group NV purchased a new position in shares of Palvella Therapeutics in the 1st quarter valued at approximately $28,000. Group One Trading LLC grew its position in Palvella Therapeutics by 151.5% during the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after purchasing an additional 200 shares during the last quarter. Russell Investments Group Ltd. purchased a new stake in Palvella Therapeutics during the 3rd quarter worth approximately $36,000. China Universal Asset Management Co. Ltd. acquired a new position in Palvella Therapeutics during the 4th quarter valued at approximately $167,000. Finally, Keybank National Association OH purchased a new position in shares of Palvella Therapeutics in the first quarter worth $228,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Stock Performance

Shares of Palvella Therapeutics stock opened at $157.24 on Monday. The company has a market capitalization of $2.25 billion, a PE ratio of -37.71 and a beta of -0.20. The company has a 50-day simple moving average of $125.26 and a two-hundred day simple moving average of $115.40. Palvella Therapeutics has a one year low of $29.38 and a one year high of $161.38.

Palvella Therapeutics (NASDAQ:PVLA) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.20) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.30). On average, equities analysts predict that Palvella Therapeutics will post -5.26 earnings per share for the current fiscal year.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.